论文部分内容阅读
目的 对一种新型脑显像剂 99TcmN(CHDTC) 2 进行临床前兔血药清除动力学、猴脑显像研究 ,以观其有无进一步临床研究的价值。方法 将用配体交换法制备的 99TcmN (CHDTC) 2 进行兔血药清除动力学、猴脑显像研究。结果 将放化纯大于 90 %的 99TcmN(CHDTC) 2 给兔静脉注射后其清除半衰期 =8.70h ;清除率 =5 2 9.5ml/h。猴脑血流显像提示 ,注药后颅内放射性逐渐升高 ,至 1h行脑SPECT显像 ,脑灰白质显像基本清楚。提示显像剂可进入血脑屏障 ,并在脑实质有较好滞留。结论 99TcmN(CHDTC) 2 是一种有潜力的新型脑显像剂 ,值得进行临床研究。
Objective To study the preclinical hematodialysis kinetics and monkey brain imaging of a novel brain imaging agent 99TcmN (CHDTC) 2 in order to observe the value of its further clinical study. Methods 99TcmN (CHDTC) 2 prepared by ligand exchange method was used to study the kinetics of rabbit plasma clearance and the study of monkey brain imaging. Results The half-life of 99TcmN (CHDTC) 2 after radiotherapy of pure 99TcmN (CHDTC) 2 was intravenously injected intravenously in rabbits = 8.70h; clearance rate was 5 2 9.5ml / h. Cerebellum cerebral blood flow imaging showed that intracranial radioactivity gradually increased after injection, and brain SPECT imaging was performed at 1h. Brain gray matter imaging was basically clear. Tip imaging agent can enter the blood-brain barrier, and in the brain parenchyma better retention. Conclusion 99TcmN (CHDTC) 2 is a potential new brain imaging agent and worthy of clinical study.